Table 1.

Baseline Characteristics of Patients With MCL (Online Only)

All Patients, n (%)	783 (100.0%)
Age at index, years
Mean (SD)	66.8 (12.0)
Median (Q1, Q3)	65 (59, 76)
Age Group, n (%)
18–44 years	20
45–54 years	79
55–64 years	270
65–79 years	283
80+ years	131
Health plan type, n (%)
HMO	102 (13.0%)
PPO	403 (51.5%)
POS	49 (6.3%)
Other	211 (27.0%)
Unknown	18 (2.3%)
Year of study index date (first diagnosis), n (%)
2012e	163 (20.8%)
2013	281 (35.9%)
2014	247 (31.6%)
2015e	92 (11.8%)
Length of follow-up (months)a
Mean (SD)	19.4 (12.8)
Median	17.9
Min, Max	0.1, 47.9
Atrial fibrillation risk statusb, n (%)
High risk	363 (46.4%)
Low risk	420 (53.6%)
CCI score
Mean (SD)	2.4 (2.4)
Median (Q1, Q3)	2 (1, 4)
Min, Max	0, 13
Daily pill burdenc
Mean (SD)	2.8 (2.8)
Median (Q1, Q3)	2 (1, 4)
Min, Max	0, 17
Average monthly costsd
Mean (SD)	$1,303 ($3,680)
Median (Q1, Q3)	$429 ($203, $934)
Min, Max	$0, $61,882

All costs are in 2016 US dollars.

CCI = Charlson Comorbidity Index; HMO = health maintenance organization; MCL = mantle cell lymphoma; POS = point of service; PPO = preferred provider organization; SD = standard deviation.

^aFollow-up time calculated as the number of days between the study index date and the end of the follow-up divided by 30.5.

^bAtrial fibrillation risk status was defined based on the method used by Chyou et al., 2015.¹⁵

^cMean number of oral medications available in-hand, on a daily basis, during the 30-day period before the study index date.

^dMean monthly all-cause costs over the 12-month baseline period (includes costs for inpatient stays, emergency department visits, office visits, other outpatient and ancillary care, and pharmacy visits) as incurred by health plans.

^eIndicates data for partial year: For 2012, data included diagnoses from July through December, and for 2015, data include diagnoses from January through June.